This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adlakha, R. C. Articles by Zwelling, L. A. Search for Related Content PubMed PubMed Citation Articles by Adlakha, R. C. Articles by Zwelling, L. A.

Modulation of 4'-(9-Acridinylamino)methanesulfon-m-anisidide-induced, Topoisomerase II-mediated DNA Cleavage by Gossypol¹

Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Our earlier studies have shown that gossypol [1,1',6,6',7,7'-hexahydroxy-5,5-diisopropyl - 3,3'-dimethyl - (2,2'-binaphthalene)-8,8'- dicarboxyaldehyde], a male contraceptive, inhibits DNA synthesis by decreasing the activities of DNA polymerase and ß, resulting in the arrest of cells in mid-S phase [L.J. Rosenberg, R.C. Adlakha, D.M. Desai, and P.N. Rao, Biochim. Biophys. Acta, 866: 258–267, 1986]. Now we have examined the effects of gossypol on another enzyme of importance to cellular functions, topoisomerase II (topo II). We have determined the consequences of gossypol treatment on 4'-(9-acridinylamino)methanesulfon-m anisidide (m-AMSA)-induced topoisomerase II-mediated, protein-associated DNA cleavage using the alkaline elution technique. In HeLa cells pretreated with gossypol (3.4–17.5 µM) for 8–16 h we observed a dose- and time-dependent decrease (50–75%) in DNA cleavage compared to that quantified in cells treated with m-AMSA alone. Gossypol by itself did not induce more than 25 rad-equivalents of DNA single-strand breaks even at the highest dose tested (26 µM). [¹⁴C]m-AMSA uptake was identical in treated and untreated cells. Pretreatment of cells with another inhibitor of DNA synthesis, thymidine, which blocks cells at G₁/S boundary increased the m-AMSA-induced DNA cleavage by 25%, suggesting that the effect of gossypol might be due to the arrest of cells in mid-S phase. In contrast to gossypol's effects on m-AMSA-induced DNA cleavage, m-AMSA-induced cytotoxicity was actually increased in gossypol pretreated cells. Gossypol blocked topo II strand passing activity (decatenation of kinetoplast DNA) of cellular extracts from HeLa cells. The inhibition of this activity by gossypol was synergistic with the inhibition produced by m-AMSA or etoposide. These data suggest that gossypol can both inhibit topo II catalytic activity and interfere with the stabilization of topo II-DNA complex formation by m-AMSA. These data indicate that the magnitude of m-AMSA-induced DNA cleavage may not necessarily parallel the magnitude of m-AMSA-induced cytotoxicity. The cytotoxicity data may rather be explained by an action of gossypol and m-AMSA to block topo II catalytic activity at a point in the enzyme's strand passing cycle prior to cleavage complex formation that might be particularly toxic to cells in S phase. Gossypol should therefore be useful in improving our understanding of the cellular role of topo II and the consequences of interference with topo II activity by active antineoplastic agents.

¹ This work was supported by a grant from the Rockefeller Foundation to R. C. A. and by Grants CA-40090 and RR5511-23, awarded by the National Cancer Institute, Department of Health and Human Services, CH-324B from the American Cancer Society, and a gift of the M. D. Anderson Annual Fund for the Chemotherapy Research Program from Henry C. Beck, Jr. of Dallas, TX, to L. A. Z.

² To whom requests for reprints should be addressed, at Department of Medical Oncology, (Box 19) The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.

Received 7/29/88. Revised 1/ 9/89. Accepted 1/17/89.

This article has been cited by other articles:

				S. DeBonis, D. A. Skoufias, L. Lebeau, R. Lopez, G. Robin, R. L. Margolis, R. H. Wade, and F. Kozielski In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities Mol. Cancer Ther., September 1, 2004; 3(9): 1079 - 1090. [Abstract] [Full Text] [PDF]